Source:		MedGen UID: 1649258


			Related Concepts
			severe acute respiratory syndrome
			Middle East respiratory syndrome

			32336586 Pharmacotherapy in COVID-19; A
			narrative review for emergency providers.

			32309622 Emerging Therapeutic Strategies
			for COVID-19 patients.

			32307245 Treatment options for COVID-19:
			The reality and challenges.

			32294562 A search for medications to treat
			COVID-19 via in silico molecular docking models
			of the SARS-CoV-2 spike glycoprotein and
			3CL protease.

			32283108 Remdesivir and SARS-CoV-2:
			Structural requirements at both nsp12 RdRp
			and nsp14 Exonuclease active-sites.

			32280433 Predicting commercially available
			antiviral drugs that may act on the novel coronavirus
			(SARS-CoV-2) through a drug-target interaction
			deep learning model.

			32277040 Structure of the RNA-dependent
			RNA polymerase from COVID-19 virus.

			32258351 Current knowledge about the antivirals
			remdesivir (GS-5734) and GS-441524 as
			therapeutic options for coronaviruses.

			32256547 Clinical trials on drug repositioning
			for COVID-19 treatment.

			32253226 An orally bioavailable broad-spectrum
			antiviral inhibits SARS-CoV-2 in human airway
			epithelial cell cultures and multiple coronaviruses
			in mice.

			32251767 Remdesivir, lopinavir, emetine, and
			homoharringtonine inhibit SARS-CoV-2
			replication in vitro.

			32247927 Remdesivir for severe acute respiratory syndrome
			coronavirus 2 causing COVID-19: An evaluation
			of the evidence.

			32247050 Insight into 2019 novel coronavirus
			- an updated intrim review and lessons from
			SARS-CoV and MERS-CoV.

			32094225 The antiviral compound remdesivir
			potently inhibits RNA-dependent RNA polymerase
			from Middle East respiratory syndrome coronavirus.

			32081636 Severe acute respiratory syndrome
			coronavirus 2 (SARS-CoV-2) and
			coronavirus disease-2019 (COVID-19):
			The epidemic and the challenges.

			32054787 Prophylactic and therapeutic remdesivir
			(GS-5734) treatment in the rhesus macaque
			model of MERS-CoV infection.

			32023685 [Potential antiviral therapeutics for
			2019 Novel Coronavirus].

			32022370 Learning from the Past: Possible
			Urgent Prevention and Treatment Options for
			Severe Acute Respiratory Infections Caused by

			32020029 Remdesivir and chloroquine
			effectively inhibit the recently emerged novel
			coronavirus (2019-nCoV) in vitro.

			31774950 A Randomized, Controlled Trial of
			Ebola Virus Disease Therapeutics.

			31389664 New Nucleoside Analogues for the
			Treatment of Hemorrhagic Fever Virus

			31233808 Broad spectrum antiviral remdesivir
			inhibits human endemic and zoonotic
			deltacoronaviruses with a highly divergent RNA
			dependent RNA polymerase.

			30974127 Advances in respiratory virus
			therapeutics - A meeting report from the 6th
			isirv Antiviral Group conference.

			29511076 Coronavirus Susceptibility to the Antiviral
			Remdesivir (GS-5734) Is Mediated by the Viral
			Polymerase and the Proofreading Exoribonuclease.

			Clinical Trials
			4302766 Expanded Access Remdesivir (RDV;

			4292899 Study to Evaluate the Safety and
			Antiviral Activity of Remdesivir (GS-5734™) in
			Participants With Severe Coronavirus Disease
			(COVID-19) (Not yet recruiting)

			4292730 Study to Evaluate the Safety and
			Antiviral Activity of Remdesivir (GS-5734™) in
			Participants With Moderate Coronavirus
			Disease (COVID-19) Compared to Standard of
			Care Treatment (Not yet recruiting)

			4280705 Adaptive COVID-19 Treatment Trial

			4257656 Severe 2019-nCoV Remdesivir RCT

			4252664 Mild/Moderate 2019-nCoV Remdesivir RCT

			3719586 Investigational Therapeutics for the Treatment
			of People With Ebola Virus Disease

     		                         Embed       Tweet       Print